Literature DB >> 26566154

Genome Editing: A New Approach to Human Therapeutics.

Matthew Porteus1.   

Abstract

The ability to manipulate the genome with precise spatial and nucleotide resolution (genome editing) has been a powerful research tool. In the past decade, the tools and expertise for using genome editing in human somatic cells and pluripotent cells have increased to such an extent that the approach is now being developed widely as a strategy to treat human disease. The fundamental process depends on creating a site-specific DNA double-strand break (DSB) in the genome and then allowing the cell's endogenous DSB repair machinery to fix the break such that precise nucleotide changes are made to the DNA sequence. With the development and discovery of several different nuclease platforms and increasing knowledge of the parameters affecting different genome editing outcomes, genome editing frequencies now reach therapeutic relevance for a wide variety of diseases. Moreover, there is a series of complementary approaches to assessing the safety and toxicity of any genome editing process, irrespective of the underlying nuclease used. Finally, the development of genome editing has raised the issue of whether it should be used to engineer the human germline. Although such an approach could clearly prevent the birth of people with devastating and destructive genetic diseases, questions remain about whether human society is morally responsible enough to use this tool.

Entities:  

Keywords:  CRISPR/Cas9; TAL effector nuclease; gene targeting; genome editing; homologous recombination; nonhomologous end-joining; stem cell; zinc finger nuclease

Mesh:

Substances:

Year:  2015        PMID: 26566154     DOI: 10.1146/annurev-pharmtox-010814-124454

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  28 in total

1.  Expression of nerve growth factor carried by pseudotyped lentivirus improves neuron survival and cognitive functional recovery of post-ischemia in rats.

Authors:  Jia-Yu Cao; Yong Lin; Yan-Fei Han; Sheng-Hao Ding; Yi-Ling Fan; Yao-Hua Pan; Bing Zhao; Qin-Hua Guo; Wen-Hua Sun; Jie-Qing Wan; Xiao-Ping Tong
Journal:  CNS Neurosci Ther       Date:  2018-02-06       Impact factor: 5.243

Review 2.  The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.

Authors:  Daniel P Dever; Matthew H Porteus
Journal:  Curr Opin Hematol       Date:  2017-11       Impact factor: 3.284

Review 3.  Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.

Authors:  Josh Tycko; Vic E Myer; Patrick D Hsu
Journal:  Mol Cell       Date:  2016-08-04       Impact factor: 17.970

4.  Knock-in editing: it functionally corrects!

Authors:  Matthew H Porteus
Journal:  Blood       Date:  2016-05-26       Impact factor: 22.113

5.  Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses.

Authors:  Nixon Niyonzima; Abigail R Lambert; Rachel Werther; Harshana De Silva Feelixge; Pavitra Roychoudhury; Alexander L Greninger; Daniel Stone; Barry L Stoddard; Keith R Jerome
Journal:  Protein Eng Des Sel       Date:  2017-07-01       Impact factor: 1.650

6.  mRNA Transfection of T-Lymphocytes by Electroporation.

Authors:  Lea-Isabell Schwarze; Boris Fehse
Journal:  Methods Mol Biol       Date:  2021

7.  Characterization of Biomolecular Helices and Their Complementarity Using Geometric Analysis.

Authors:  Kevin Hauser; Yiqing He; Miguel Garcia-Diaz; Carlos Simmerling; Evangelos Coutsias
Journal:  J Chem Inf Model       Date:  2017-04-06       Impact factor: 4.956

Review 8.  Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.

Authors:  Isabelle Rivière; Michel Sadelain
Journal:  Mol Ther       Date:  2017-04-26       Impact factor: 11.454

9.  CRISPR/Cas9 genome editing in human hematopoietic stem cells.

Authors:  Rasmus O Bak; Daniel P Dever; Matthew H Porteus
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

10.  CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.

Authors:  Daniel P Dever; Rasmus O Bak; Andreas Reinisch; Joab Camarena; Gabriel Washington; Carmencita E Nicolas; Mara Pavel-Dinu; Nivi Saxena; Alec B Wilkens; Sruthi Mantri; Nobuko Uchida; Ayal Hendel; Anupama Narla; Ravindra Majeti; Kenneth I Weinberg; Matthew H Porteus
Journal:  Nature       Date:  2016-11-07       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.